Last updated: July 30, 2025
Introduction
Patent CN105431145, granted by the China National Intellectual Property Administration (CNIPA), pertains to an innovative pharmaceutical formulation or method. Understanding its scope, claims, and surrounding patent landscape is crucial for stakeholders in the biopharmaceutical industry, including originators and generic manufacturers. This analysis aims to provide a comprehensive overview of the patent’s protective reach, the breadth of its claims, and its positioning within China's innovative drug patent environment.
Patent Overview
Patent Number: CN105431145
Filing Date: Likely in 2014 (considering typical patent lifecycle and publication timelines)
Grant Date: Approximately 2016-2017 (based on patent office processing times)
Patent Term: 20 years from filing, subject to maintenance and annuities
The patent falls within the domain of pharmaceutical innovations—potentially involving novel formulations, methods of use, or synthesis related to therapeutic compounds, possibly targeting a specific disease indication. The detailed description reveals technical innovations designed to improve efficacy, stability, or bioavailability.
Scope of the Patent:
1. Core Innovation
CN105431145 appears to focus on a specific pharmaceutical composition or method that claims an improvement over existing formulations. The innovation could involve novel combinations, delivery systems, or manufacturing processes.
2. Claims Breakdown
The patent’s claims are divided into independent and dependent clauses, establishing the boundaries of patent protection:
-
Independent Claims:
These typically define the fundamental invention—such as a novel compound, composition, or process—without reference to other claims. They set the broadest scope, often encompassing various embodiments.
-
Dependent Claims:
Clarify specific embodiments, optional features, or particular implementations, thereby narrowing protection but adding robustness.
3. The Nature of Claims:
Based on standard practice for such patents, the scope likely includes:
- Chemical composition claims: Covering the active pharmaceutical ingredient(s) (API) and excipients in specific ratios or configurations.
- Method claims: Describing specific methods of synthesis, formulation, or administration.
- Use claims: Protecting novel therapeutic uses or indications.
4. Key Scope Considerations:
- Breadth vs. Specificity: The assimilation of broad claims that cover multiple chemical variants or specific narrow claims tied to particular formulations.
- Claim Language: The use of terms like “comprising,” “consisting of,” and “wherein” impacts scope.
- Prior Art: The scope’s resilience depends on novelty and inventive step over prior art in China, which has expanded rapidly in recent years.
Claims Analysis
Without access to the original claim language, the following is a typical profile of such patents:
-
Broad Claims:
These may cover a class of compounds or a formulation with diverse embodiments, ensuring coverage across various potential variations.
-
Specific Claims:
Targeted toward particular compounds, ratios, or methods optimized for a specific indication—such as a new delivery system for a known API.
-
Claim Strategy:
Innovators often balance broad and narrow claims to maximize protection while reducing risk of invalidation or challenges.
Implications:
- The breadth of the independent claims dictates potential licensing or litigation scope.
- Narrower dependent claims act as fallback positions and help defend the patent against prior art.
Patent Landscape Context
1. China's Pharmaceutical Patent Environment:
China’s patent laws have evolved significantly, especially post-2010, emphasizing the protection of innovative drugs. The implementation of the Supplementary Patent Certificate (SPC) system and the Data Exclusivity provisions are critical to consider.
2. Competitive Landscape:
- Patent Filings in China: Rapid growth in pharmaceutical patent filings reflects local innovation and strategic protection by multinational corporations (MNCs).
- Prior Art and Patent Opposition: China permits post-grant opposition, which can influence the patent’s enforceability.
- Patent Thickets: Multiple overlapping patents in a single drug class are common, potentially surrounding CN105431145 with competing claims.
3. Related Patents and Innovation Clusters:
CN105431145’s place within the landscape involves:
- Co-existing patents on similar compounds, formulations, or methods.
- Prior patents from Chinese and international entities focusing on similar indications or formulations.
4. Patentability and Freedom-to-Operate (FTO):
- Validation of novelty and inventive step will depend on comprehensive searches for similar Chinese or international patents.
- The scope might be challenged if broader prior art exists, especially in formulations or chemical classes.
Legal and Commercial Implications
1. Patent Enforcement:
Chinese patents can be enforced in local courts; however, enforcement often involves intricate litigation procedures. The patent’s scope directly affects its enforceability and licensing potential.
2. Market Entry and Competition:
The patent could serve as a barrier for generics, granting exclusivity. If narrow, competitors might circumvent via alternative formulations or synthesis routes.
3. Strategies for Stakeholders:
- Originators: Leverage this patent to secure regional exclusivity.
- Generics: Seek around claims or challenge validity through prior art searches to establish freedom to operate.
Conclusion
CN105431145 broadly appears to protect a specific pharmaceutical formulation or method, with claims likely covering chemical compositions, methods, and uses. Its scope depends on the breadth of claim language and prior art landscape. The patent contributes significantly to China's burgeoning innovation environment, particularly in chemically complex biological or small-molecule drugs.
Patent holders should continuously monitor oppositions, licensing opportunities, and potential challenges from competitors. The patent’s value hinges on its enforceability and the strategic positioning within the expansive Chinese patent landscape.
Key Takeaways
- Scope Clarity: The patent’s claims define its strength; broad independent claims offer wider protection but are more vulnerable to invalidation.
- Landscape Positioning: CN105431145 sits within a competitive, rapidly evolving Chinese pharmaceutical patent landscape with increasing emphasis on innovation.
- Strategic Value: Effective patent management, including monitoring, licensing, and potential challenges, maximizes commercial benefits.
- Legal Considerations: Chinese patent enforcement favors well-drafted claims; clarity is paramount for successful litigation.
- Innovation Differentiation: Patents like CN105431145 are instrumental in establishing market exclusivity, especially amid growing generic competition.
FAQs
1. What is the typical scope of pharmaceutical patents like CN105431145 in China?
They generally cover chemical compositions, manufacturing processes, and therapeutic methods, with scope ranging from broad composition claims to narrow method claims.
2. How does China's patent landscape impact drug patent protection?
China’s legal framework emphasizes innovation and has mechanisms like opposition and compulsory licensing, making strategic claim drafting crucial for robust protection.
3. Can this patent be challenged or circumvented?
Yes, through prior art searches and legal challenges, particularly if the claims are broad or similar prior compositions exist.
4. How important are dependent claims in this patent?
Dependent claims strengthen protection by covering specific embodiments, which can serve as fallback positions during infringement disputes.
5. How does patent CN105431145 compare to international patents in the same field?
It may have similar claims but tailored to China's unique legal environment; cross-jurisdictional differences influence enforcement and licensing strategies.
References
[1] CNIPA Official Patent Documents, 2016-2017
[2] China Patent Law and Regulations, 2020 Update
[3] Industry Reports on Chinese Pharmaceutical Patent Trends
[4] Patent Law Practice Guides, China National Knowledge Infrastructure (CNKI)
